Importantly, while HALP had previously been validated mainly in patients with well-preserved liver function (e.g., Child–Pugh A), we included a broader range of liver dysfunction (Child–Pugh A to C), which expanded the applicability of our findings. The gene discussed is NAT10; the disease is Decreased liver function.